-
1 Comment
Aphria Inc is currently in a long term uptrend where the price is trading 31.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.5.
Aphria Inc's total revenue rose by 33.1% to $161M since the same quarter in the previous year.
Its net income has dropped by 1421.0% to $-121M since the same quarter in the previous year.
Finally, its free cash flow grew by 75.7% to $-16M since the same quarter in the previous year.
Based on the above factors, Aphria Inc gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | NYSE |
CurrencyCode | USD |
ISIN | CA03765K1049 |
Market Cap | 7B |
---|---|
Beta | 2.62 |
PE Ratio | None |
Target Price | None |
Dividend Yield | 0.0% |
Tilray Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The company offers cannabis-lifestyle and consumer packaged goods; and hemp-based foods and alcoholic beverages. It offers medical cannabis in extracts and dried flower forms; and cannabis extracts, including purified oil drops and capsules. The company supplies cannabis extract products to patients, physicians, pharmacies, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company was formerly known as Aphria Inc. and changed its name to Tilray, Inc. Tilray Inc. is based in Leamington, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for APHA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025